Provided by Tiger Trade Technology Pte. Ltd.

Fidelity MSCI Health Care Index ETF

80.60
+0.02000.02%
Post-market: 80.600.00000.00%19:30 EDT
Volume:210.62K
Turnover:16.95M
Market Cap:3.49B
PE:- -
High:80.81
Open:80.81
Low:80.23
Close:80.58
52wk High:85.46
52wk Low:67.77
Shares:43.35M
Float Shares:43.35M
Volume Ratio:0.47
T/O Rate:0.49%
Dividend:1.02
Dividend Rate:1.27%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Johnson: AI Providers Committed to Building Trust

THOMSON REUTERS
·
Sep 30

Johnson: We Can Keep Edge in a Safe Way

THOMSON REUTERS
·
Sep 30

Johnson: We'LL Continue to Assess and Deliberate in Coming Days

THOMSON REUTERS
·
Sep 30

US Drug Lobby Group PhRMA Names Former House Leader Cantor as CEO

Reuters
·
Sep 30

Cboe data shows mixed options sentiment in UnitedHealth with shares down 1.58%

TIPRANKS
·
Sep 30

AbbVie Shows Pipeline-Driven Upside Beyond Core Immunology Franchise, BofA Says

MT Newswires Live
·
Sep 29

Cigna: Announces Exclusive Agreement with UnitedHealth Global to Endorse Ghb as Preferred International Health Insurer - Website

THOMSON REUTERS
·
Sep 29

Cigna Global Health Benefits Signs Exclusive Endorsement Deal with UnitedHealthcare Global

Reuters
·
Sep 29

Ginkgo Datapoints, Apheris, AbbVie, and Others Form Antibody Developability Consortium

MT Newswires Live
·
Sep 29

Pharma Sector Doubles Down on AI to Slash Costs, Timelines

Reuters
·
Sep 29

J&J : Bofa Global Research Raises Price Objective to $278 from $263

THOMSON REUTERS
·
Sep 29

AbbVie Partners with Valkai to Deploy AI Across Clinical Development

Reuters
·
Sep 29

Abbvie - to Deploy AI Via Valkai Partnership to Improve Clinical Research Efficiency

THOMSON REUTERS
·
Sep 29

Abbvie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development

THOMSON REUTERS
·
Sep 29

Allergan Aesthetics Receives Health Canada Authorization for Boey® (Trenibotulinumtoxine), the First and Only Rapid-Onset, Short-Duration Neurotoxin for Frown Lines

THOMSON REUTERS
·
Sep 29

J&J Says Imaavy Shows Sustained Disease Control Through Two Years in Adolescent Myasthenia Gravis Study

Reuters
·
Sep 29

J&J - no New Safety Signals Identified Through Two Years of Imaavy Treatment

THOMSON REUTERS
·
Sep 29

J&J - Presents New Data on Imaavy in Generalized Myasthenia Gravis

THOMSON REUTERS
·
Sep 29

J&J - Two-Year Phase 2/3 Data Shows Sustained Disease Control and Reduced Corticosteroid Use in Adolescents

THOMSON REUTERS
·
Sep 29

Eli Lilly Reports Zepbound Showed 4.5% Greater Weight Loss Than Novo Nordisk's Wegovy HD

MT Newswires Live
·
Sep 29